CD19 and diffuse large B-cell lymphoma: Loncastuximab tesirine, an ADC targeting CD19, was being evaluated in combination with rituximab in a Phase II trial in previously untreated unfit/frail patients with DLBCL; however, the study was terminated due to adverse respiratory safety signals (LOTIS‐9; NCT05144009).86, 90, 91